

H3

--ABSTRACT OF THE DISCLOSURE

IGF-I or an analogue thereof is administered to delay the clinical onset of diabetes, to reduce the occurrence of beta cell destruction in a subject having a high risk of developing diabetes, to provide a regulating effect on spleen T cells in a subject having a high risk of developing diabetes, or to reduce the likelihood of the occurrence of clinical diabetes in a subject having a high risk of developing diabetes.--